Pfizer (PFE) Change in Cash (2009 - 2026)

Pfizer has disclosed Change in Cash across 18 years of filings, most recently posting $563.0 million for Q1 2026.

• In Q1 2026, Change in Cash rose 50.13% year-over-year to $563.0 million; the TTM figure through Mar 2026 stood at $279.0 million (up 108.76% YoY), while the FY2025 annual figure was $91.0 million, up 105.03% from the prior year.
• Change in Cash climbed to $563.0 million in Q1 2026, from -$196.0 million in the prior quarter.
• Over the last five years, Change in Cash for PFE reached as high as $1.8 billion in Q2 2023 and fell as low as -$2.1 billion in Q1 2024.
• The 5-year median for Change in Cash is $213.0 million (2025), against an average of -$84.1 million.
• Annual changes were most pronounced in 2022 — Change in Cash surged 3626.67% — and 2024, when it tumbled 429.91%.
• A 5-year view of Change in Cash shows it stood at -$646.0 million in 2022, then soared by 51.08% to -$316.0 million in 2023, then tumbled by 458.54% to -$1.8 billion in 2024, then soared by 88.9% to -$196.0 million in 2025, then soared by 387.24% to $563.0 million in 2026.
• According to Business Quant data, Change in Cash over the past three periods registered $563.0 million, -$196.0 million, and -$301.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.